{"prompt": "['Protocol RS-001', 'Confidential', 'Nisonger Child Behavioral Rating Form (NCBRF) [2,3]', 'Both will be completed at baseline, at the completion of maintenance, and at the', 'completion of the 3-month follow-up period.', 'III.', 'Weekly whole blood rapamycin trough levels for three consecutive weeks.', '6', 'PARTICIPANT SELECTION', '6.1', 'Study Population', 'Participants with a diagnosis of medically intractable epilepsy who meet all of the inclusion and', 'none of the exclusion criteria will be eligible for participation in this study. Participants must be', 'enrolled before study procedures begin.', '6.2', 'Inclusion Criteria', '1. Written informed consent (and assent when applicable) obtained from participant or', \"participant's legal representative\", '2. Be willing and able to adhere to the study visit schedule and other protocol requirements', '3. Male or female >3 and <26 years of age at Visit 1', 'b. Because no dosing or adverse event data are currently available on the use of ABI-', '009 or other mTOR inhibitors in participants <3 years of age, these young children', 'are excluded from this study.', '4. Documentation of a diagnosis of medically intractable epilepsy as defined by the failure of at', 'least 2 appropriately dosed and tolerated AEDs to eliminate all clinical seizures over a 6-', 'month period, prior to epilepsy surgery', '5. Documentation of resective epilepsy surgery following appropriate pre-surgical evaluation', '6. Documentation of continued clinical seizures that persist at least 3 months following', 'resective epilepsy surgery. In order to proceed with enrollment and study drug initiation,', 'participants will have to have had >8 seizures in the last 30 days without 2 consecutive weeks', 'of seizure freedom, as noted by a daily seizure diary.', '7. Documentation that the participant is not a candidate for or refuses any additional resective', 'epilepsy surgery', '8. Participants must have adequate bone marrow function (ANC 1,000/mm\u00b3, platelet count of', '>100,000/mm\u00b3, and hemoglobin >9 gm/dL) before study drug dosing.', '9. Participants must have adequate liver function (SGPT/ALT <5 times ULN and bilirubin <5', 'times ULN) before study drug dosing.', '10. Participants must have adequate renal function, defined as: Creatinine clearance or', 'radioisotope GFR>70mL/min/1.73 m2 or a serum creatinine before study drug dosing based', 'on age/gender as follows:', 'Version 2', 'Version Date: October 31, 2018', 'Page 37 of 72']['Protocol RS-001', 'Confidential', 'Age', 'Maximum Serum', 'Creatinine (mg/dL)', 'Male', 'Female', '3 to < 6 years', '0.8', '0.8', '6 to < 10 years', '1', '1', '10 to < 13 years', '1.2', '1.2', '13 to < 16 years', '1.5', '1.4', '16 years', '1.7', '1.4', 'The threshold creatinine values in this table were derived from the Schwartz', 'formula for estimating GFR utilizing child length and stature data published', 'by the CDC.', '11. Participants must have a fasting cholesterol level <350 mg/dL and triglycerides <400 mg/dL', 'before starting study drug. In case one or both of these are exceeded, the participant can only', 'be included after initiation of appropriate lipid lowering medication and documentation of', 'cholesterol <350mg/dL and triglycerides <400mg/dl before study drug dosing.', '12. Participants must have normal oxygen saturation before study drug dosing.', '13. The effects of ABI-009 on the developing human fetus at the recommended therapeutic dose', 'are unknown. For this reason and because rapamycin is known to be teratogenic, female', 'participants of child-bearing potential and men must agree to use adequate contraception', '(hormonal or barrier method of birth control; abstinence) prior to study entry and for the', 'duration of study participation. Should a female participant become pregnant or suspect she', 'is pregnant while participating in this study, she should inform her treating physician', 'immediately.', 'a. Participants of child bearing potential must not be breastfeeding or pregnant as', 'evidenced by a negative pregnancy test at enrollment and before study drug initiation.', '6.3', 'Exclusion Criteria', '1. For females of child bearing potential:', 'a. Positive pregnancy test at Visit 1, or', 'b. Lactating, or', 'c. Unwilling to practice a medically acceptable form of contraception (acceptable forms', 'of contraception: abstinence, hormonal birth control, intrauterine device, or barrier', 'method plus a spermicidal agent), unless surgically sterilized or postmenopausal', 'during the study.', '2. Participant has any other condition that, in the opinion of the Site Investigator/designee,', 'would preclude informed consent or assent, make study participation unsafe, complicate', 'interpretation of study outcome data, or otherwise interfere with achieving the study', 'objectives.', '3. Participants has received immunization with attenuated live vaccines within one week of', 'study entry and/or is planning to receive immunization with attenuated live vaccines during', 'study period. Examples of live vaccines include intranasal influenza, measles, mumps,', 'rubella, oral polio, BCG, yellow fever, varicella and TY21a typhoid vaccines. Close contact', 'Version 2', 'Version Date: October 31, 2018', 'Page 38 of 72']\n\n###\n\n", "completion": "END"}